Genfit

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Genfit sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 1 currently recruiting 6 completed early-phase tilt top decile by trial count

Genfit: 11 sponsored US clinical trials, 1 recruiting.

Genfit sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Severe Hepatic Impairment, with 1 trials.

Top-decile sponsor footprint

Genfit ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

6 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (60.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

NCT05874414
COMPLETED Phase 1

Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

NCT07110441
TERMINATED Phase 2

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
TERMINATED Phase 2

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

NCT05900050
COMPLETED Phase 1

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

NCT05368935
COMPLETED Phase 1

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT05116826
TERMINATED Phase 2

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

NCT03883607
COMPLETED Phase 1

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT03765671
COMPLETED Phase 2

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

NCT03124108
TERMINATED Phase 3

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02704403
COMPLETED Phase 2

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT01694849

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 5
Phase 3 1

Therapeutic Areas

Severe Hepatic Impairment 1
Moderate Hepatic Impairment 1
Liver Disease 1
Hepatic Impairment 1
Liver Diseases 1
Cholangiocarcinoma 1
Pharmacokinetics 1

What is open in the Genfit pipeline

1 recruiting of 11 indexed (9% open); 6 completed (55%).

Phase mix: 1 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Severe Hepatic Impairment (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Genfit: open-pipeline peers nationwide

Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

Genfit sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%2%4%6%8%10% Total trials Recruiting share GenfitAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeAlkermesDBV TechnologiesFlorida Gulf Coast UniversityHiberCell
Genfit sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Genfit sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Genfit page

11 registered trials is a research-attention snapshot, not an endorsement of Genfit or any single study.

  • 1 of Genfit's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Severe Hepatic Impairment is the condition Genfit studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Severe Hepatic Impairment trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Genfit pipeline card: 11 registered trials from official public datasets.Report a data error.